Professor Goh leads a clinical research team that studies novel drugs for treatment of cancer. These studies are designed to define clinical pharmacology, and to determine anticancer effects. In addition, a laboratory group he leads is involved with studies to optimise combination of molecular pathway inhibitors for cancer treatment with the intent to translate these findings to clinical trials.
Professor Goh’s research group active investigates pharmacogenetics in the context of understanding ethnic and geographical factors that influence cancer drug effects. The hypothesis is that though intercontinental population variability of genetic polymorphisms form a small fraction of total interindividual variability, gene variants that affect drug disposition and receptor function may have large enough effects to account for ethnic or geographic differences in drug action. This would likely be clinically relevant for cancer drugs, which generally have narrow therapeutic windows.
Deputy Director, Cancer Science Institute of Singapore, NUS
Programme Leader and Senior Principal Investigator, Cancer Science Institute of Singapore, NUS
Deputy Director (Research), National University Cancer Institute, Singapore (NCIS), NUHS
| Year(s) | Degree (if applicable) | Institute |
| 1989 | MBBS | Bachelor of Medicine, Bachelor of Surgery |
| 1994 | M.Med (Int) | Master of Medicine (Internal Medicine with Gold Medal) |
| 2008 – Present | Deputy Director, Cancer Science Institute of Singapore, National University of Singapore |
| 2008 – Present | Programme Leader and Senior Principal Investigator, Cancer Science Institute of Singapore, National University of Singapore |
| 2018 – Present | Deputy Director (Research), NCIS |
| 2005 – Present | Senior Consultant, Medical Oncology |
| 2008 – 2017 | Head and Senior Consultant, Department of Haematology-Oncology, NUHS |
| 2000 – 2005 | Consultant, Medical Oncology |
| 1999 – 1999 | Associate Consultant, Medical Oncology |
| 1998 – 1999 | Senior registrar, Medical Oncology |
| 1997 – 1998 | Visiting fellow, Clinical Pharmacology, Medical Oncology, Head and Neck Oncology, Thoracic Oncology, University of Chicago |
| 1995 – 1997 | Registrar, Medical Oncology |
| 1994 – 1995 | Resident, Emergency (Specialist), National University Hospital |
| 1994 | Resident, General Medicine (Specialist) Neurology, Tan Tock Seng Hospital |
| 1993 – 1994 | Resident, Medical Oncology (Specialist), Singapore General Hospital |
| 1992 – 1993 | Resident, General Medicine, Rheumatology, Tan Tock Seng Hospital, Singapore |
| 1990 – 1992 | Medical Officer (doctrine/training), Singapore Armed Forces, Secretary of Advanced Trauma Life Support Course committee responsible for bringing the first ATLS course to Singapore. |
| 1989 – 1990 | Intern, General Medicine, Obstetric and Gynecology, Surgery, National University Hospital |
WANG Lingzhi
PhD Senior Research Scientist
He has specific expertise in the fields of pharmacokinetics, cancer biomarkers and combination therapeutics against cancer.
CHONG Qingyun
Research Fellow
The role of Trefoil Factor 3 in drug resistance in mammary carcinoma.
FHU Chee Wai
Research Fellow
Understanding the metabolic plasticity of chemoresistant lung cancer cells and develop a therapeutic strategies to target them
KONG Li Ren
Research Fellow
Understanding mechanisms to chemoresistance and exploring novel therapeutic strategies in squamous cell carcinoma.
Jayshree HIRPARA
Research Associate
Pre-clinical analysis to check the effect of STAT3 inhibitor on tumor cells.
EU Jie Qing
Research Assistant
Finding combination therapies on the treatment of oncogene-addicted cancer cells.
Nur Afiqah Binte MOHAMED SALLEH
Research Assistant
Understanding the role of MET mutation in squamous cell carcinoma.
Win Lwin THUYA
Research Assistant
He possesses sound knowledge in biomedicine and has good experience in animal studies. His research is focused on exosome-derived cancer biomarker investigation.
Amelia Jieying LAU
Laboratory Executive
Experienced in cell based assays such as drug sensitivity assay on cell viability, siRNA knockdown and pooled lentiviral shRNA library screen. Other skills include Western Blot, microarray, mouse work, bacteria culture and cloning.
TEO Jun Ting
Laboratory Executive
BUI Ngoc Linh Chi
PhD Student
Exploring the role of cell cycle proteins in Nasopharyngeal Carcinoma.
XU MingGe
Research Assistant
Yee Yi Hui Michelle
PhD Student
URedox dependent activation of NF-KB signalling in cancer.
Copyright © 2020 Cancer Science Institute of Singapore (CSI). All Rights Reserved.
